Trial site
Lynn Health Science Institute
Oklahoma City, Oklahoma 73112, United StatesNot linked to an institution yet
- 14running trials
- 18closed trials
The trials here
What the 32 trials at this site are about, from their registry records.
- Phase
- Phase 320 trials
- Phase 25 trials
- Phase 13 trials
- Phase 1/22 trials
- Phase 41 trial
- Status
- Completed14 trials
- Active, not recruiting10 trials
- Recruiting4 trials
- Terminated4 trials
- Lead sponsor
- Amgen4 trials
- Eli Lilly and Company4 trials
- ModernaTX, Inc.4 trials
- Pfizer4 trials
- Biogen2 trials
- and 12 more
Running trials
Recruiting
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
NCT07837973· Phase 2· Alveus Therapeutics, Inc.· Source
Contact: Lacey Dietz
Active, not recruiting
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
NCT07477704· Phase 2· Regeneron Pharmaceuticals· Source
Recruiting
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
NCT07575399· Phase 3· Amgen· Source
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout
NCT07388498· Phase 3· Amgen· Source
Active, not recruiting
Study of GS-0151 in Participants With Rheumatoid Arthritis
NCT06902519· Phase 1· Gilead Sciences· Source
Active, not recruiting
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
NCT06565611· Phase 2· Palatin Technologies, Inc· Source
Active, not recruiting
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
NCT05774756· Phase 3· Rhythm Pharmaceuticals, Inc.· Source
Active, not recruiting
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398· Phase 3· Pfizer· Source
Active, not recruiting
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
NCT05164094· Phase 1/2· ModernaTX, Inc.· Source
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455· Phase 3· Eisai Inc.· Source
Active, not recruiting
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
NCT02951598· Eli Lilly and Company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
NCT06046443· Phase 2· Rhythm Pharmaceuticals, Inc.· Source
Completed
A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
NCT06229145· Phase 4· Amgen· Source
Completed
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
NCT06178991· Phase 3· BioNTech SE· Source
Completed
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· Phase 3· Boehringer Ingelheim· Source
Completed
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
NCT05975099· Phase 1/2· ModernaTX, Inc.· Source
Completed
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05704738· Phase 3· Amgen· Source
Completed
A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
NCT05696847· Phase 1· Eli Lilly and Company· Source
Completed
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza
NCT05596734· Phase 2· BioNTech SE· Source
Completed
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
NCT05566639· Phase 3· ModernaTX, Inc.· Source
Completed
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
NCT05540522· Phase 3· Pfizer· Source
Completed
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
NCT05456529· Phase 3· Incyte Corporation· Source
Terminated
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
NCT05310071· Phase 3· Biogen· Source
Completed
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir
NCT05169580· Phase 1· Fulcrum Therapeutics· Source
Terminated
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
NCT05085366· Phase 3· ModernaTX, Inc.· Source
Completed
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
NCT04392154· Phase 3· Eli Lilly and Company· Source
Terminated
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
NCT04241068· Phase 3· Biogen· Source
Terminated
Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031
NCT03573882· Phase 3· Pfizer· Source
Completed
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT03422822· Phase 3· Pfizer· Source
Report an error